- Home
- RGA vs MDGL Comparison
RGA vs MDGL Comparison
Compare RGA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGA | MDGL |
|---|---|---|
| Founded | 1973 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 12.8B |
| IPO Year | 1996 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RGA | MDGL |
|---|---|---|
| Price | $245.61 | $534.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $241.50 | ★ $674.45 |
| AVG Volume (30 Days) | 301.2K | ★ 365.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ 64.86 | N/A |
| EPS | ★ 11.99 | N/A |
| Revenue | ★ $23,698,000,000.00 | $180,133,000.00 |
| Revenue This Year | $11.38 | $58.39 |
| Revenue Next Year | $6.11 | $48.55 |
| P/E Ratio | $20.52 | ★ N/A |
| Revenue Growth | ★ 7.20 | N/A |
| 52 Week Low | $178.21 | $393.61 |
| 52 Week High | $251.00 | $615.00 |
Technical Indicators
Market Signals| Indicator | RGA | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 57.58 | 54.85 |
| Support Level | $239.23 | $529.02 |
| Resistance Level | $251.00 | $545.13 |
| Average True Range (ATR) | 4.34 | 19.22 |
| MACD | -0.60 | 2.59 |
| Stochastic Oscillator | 52.46 | 77.29 |
Price Performance
Historical ComparisonAbout RGA Reinsurance Group of America Incorporated
Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.